Artiva Biotherapeutics is focused on developing and commercializing off-the-shelf cell therapies for patients with hematologic malignancies or solid tumors. Our pipeline of universal and targeted product candidates exploits the innate biology and safety features of Natural Killer (NK) cells, while seeking to enhance their efficacy through antibody combination therapy and genetic engineering.
Our product pipeline will include unmodified cord blood-derived NK cells, genetically modified and gene edited NK-CARs, and iPSC-derived NK cells, each building on the discovery, preclinical development, and large scale manufacturing success of our corporate partner. The core technology for our initial product candidates is currently being evaluated by our partner in Phase 2 clinical studies in Korea, and we expect to initiate U.S. clinical trials for the first Artiva candidate, AB-101, in 2020.
Tom Farrell (Founding President & CEO) has a twenty-year track record as a biotech entrepreneur. He was most recently President and CEO of Bellicum Pharmaceuticals, a pioneer in the development of controllable cell therapies. At Bellicum, which he built from a virtual startup through a highly successful IPO in 2014, raising a total of more than $300 million in the process, Tom brought five genetically modified cell therapies into clinical development, including one into pivotal trials. Previously, he was the founding President and CEO of Cylene Pharmaceuticals, a small molecule rational drug design company targeting secondary DNA structures to regulate oncogene expression. Tom received his B.A. in Engineering from the University of Cambridge and MBA from Stanford Graduate School of Business, where he was an Arjay Miller scholar.
Peter Flynn PhD (Chief Technology Officer) has over 18 years of biotech industry experience. He was most recently EVP of Orexigen Therapeutics where he led clinical development, medical affairs, regulatory affairs and safety functions. Prior to Orexigen, Pete was SVP, Early Program Development at Fate Therapeutics where he was responsible for the regenerative medicine programs and development of the iPSC platform. Prior to Fate he was Vice President of Research at Ren Pharmaceuticals. Pete started his industry career as one of the first employees at the antibody therapeutics company KaloBios Pharmaceuticals, where as head of biochemistry he helped build both the platform technology and monoclonal therapeutic pipeline. Pete holds a BSc in Molecular Biology from University College London, a PhD in Biochemistry from Imperial Cancer Research Fund (CRUK) and was a postdoctoral fellow at the University of California, San Francisco Cancer Center.
Jason B Litten MD (Chief Medical Officer) has over 11 years of biotech industry experience. He was most recently CMO at Optera Therapeutics. Prior to Optera, Jason was VP of Clinical Development at Juno Therapeutics, a cell therapy company where he oversaw clinical development for all of Juno’s solid tumor CAR and TCR programs. Prior to Juno he was Vice President of Clinical Development at Clovis Oncology where he led the lucitanib and rociletinib clinical programs. Jason started his industry career in Clinical Development at Amgen supporting development of trebananib and panitumumab (Vectibix©). Jason holds a BS from Cornell University and MD from Emory University. He was a Resident Physician in General Pediatrics at University of Miami and Clinical Fellow in Pediatric Hematology & Oncology at UT Southwestern.
Our Corporate Partner
Artiva is being launched with the backing of our principal corporate partner, GC LabCell, which brings to the relationship significant assets, capabilities and experience in the discovery, development, large scale manufacturing and clinical evaluation of NK cell therapies.
We are seeking highly skilled, collaborative, entrepreneurial team members who are committed to improving the lives of cancer patients through cellular immunotherapy. Check out our Careers page for more details.